Kiora Pharmaceuticals to Participate in Piper Sandler Virtual Ophthalmology Symposium

Rhea-AI Summary

Kiora Pharmaceuticals (NASDAQ:KPRX) will take part in an investor fireside chat at the Piper Sandler Virtual Ophthalmology Symposium.

The live presentation is scheduled for Thursday, July 9, 2026 at 2:30 p.m. EDT and will be webcast with a replay available for 90 days.

News Market Reaction – KPRX

-1.13%

-1.13% Session close to close

In the Jul 2 session, KPRX declined 1.13%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

Participation in the Piper Sandler ophthalmology symposium gives Kiora a platform to highlight recen...

Analysis

Participation in the Piper Sandler ophthalmology symposium gives Kiora a platform to highlight recent clinical and financing milestones. Investors may watch for any incremental disclosures from the fireside chat while weighing prior dilution and the company’s execution on its pipeline.

Key Figures

Symposium date: July 9, 2026 Presentation time: 2:30 p.m. EDT Replay availability: 90 days

3 metrics

Symposium date July 9, 2026 Piper Sandler Virtual Ophthalmology Symposium presentation date

Presentation time 2:30 p.m. EDT Scheduled start time for investor fireside chat

Replay availability 90 days Length of time webcast replay will be accessible

Historical Context

5 past events · Latest: Jun 18 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Jun 18	Preclinical data update	Positive	-1.6%	Preclinical data showed KIO-300 suppressed seizure activity in epilepsy model.
May 08	Earnings report	Neutral	+0.0%	Q1 2026 financial results and pipeline update, including ABACUS-2 enrollment status.
Apr 14	Clinical trial update	Neutral	+0.0%	Publication of Phase 1 ABACUS-1 KIO-301 data and Phase 2 trial initiation.
Apr 07	Private placement	Negative	+6.9%	Private placement for up to $24M with upfront proceeds and warrant tranches.
Apr 02	Management change	Neutral	+4.1%	Chief Development Officer departure and continued enrollment in KIO-301/KIO-104.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Over recent months, KPRX’s stock reactions have generally been modest, with stronger moves tied to financing and management news rather than routine scientific or earnings updates.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Encinitas, California--(Newsfile Corp. - July 2, 2026) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) today announced that it will participate in an investor fireside chat at the Piper Sandler Virtual Ophthalmology Symposium.

Presentation Details

Date: Thursday, July 9, 2026
Time: 2:30 p.m. Eastern Daylight Time
Live Presentation: Available on Kiora's Investor Relations homepage at ir.kiorapharma.com
Replay: Available for 90 days on Kiora's Investor Relations Events page at ir.kiorapharma.com/news-events/events

About Kiora Pharmaceuticals

Kiora Pharmaceuticals is a clinical-stage biotechnology company developing advanced therapies for retinal disease. We target critical pathways underlying retinal diseases using innovative small molecules to slow, stop, or restore vision loss. KIO-301 is being developed initially for the treatment of retinitis pigmentosa, with potential to expand into choroideremia and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of macular edema due to retinal inflammation. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase (DHODH).

In addition to news releases and SEC filings, we expect to post information on our website, www.kiorapharma.com, and social media accounts that could be relevant to investors. We encourage investors to follow us on X and LinkedIn as well as to visit our website and/or subscribe to email alerts.

Contact:
investors@kiorapharma.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/303675

FAQ

When will Kiora (NASDAQ:KPRX) present at the Piper Sandler Virtual Ophthalmology Symposium?

Kiora will present on Thursday, July 9, 2026, at 2:30 p.m. EDT. According to Kiora, the appearance is part of an investor fireside chat during the Piper Sandler Virtual Ophthalmology Symposium.

How can investors watch Kiora's July 9, 2026 Piper Sandler symposium presentation?

Investors can watch the live presentation via webcast on Kiora's Investor Relations homepage. According to Kiora, the event will be accessible through ir.kiorapharma.com at the scheduled time.

Will a replay of Kiora (KPRX) Piper Sandler Virtual Ophthalmology Symposium chat be available?

Yes, a replay will be available for 90 days after the event. According to Kiora, investors can access the replay on the Investor Relations Events page at ir.kiorapharma.com/news-events/events.

Where is the Kiora Pharmaceuticals investor fireside chat being hosted on July 9, 2026?

The fireside chat will be hosted virtually as part of the Piper Sandler Virtual Ophthalmology Symposium. According to Kiora, the session is accessible online through the company’s Investor Relations website.

What time zone is used for Kiora's Piper Sandler Virtual Ophthalmology Symposium presentation time?

The presentation time of 2:30 p.m. is listed in Eastern Daylight Time. According to Kiora, this schedule applies to the live webcast of the investor fireside chat.